# Page 100 Audit — Methods: Table 2 PICOM Continued (33 Spans)

## Page Identity
- **PDF page**: S99 (Methods for Guideline Development — www.kidney-international.org)
- **Content**: Table 2 continuation — PICOM questions for antiplatelet (continued), smoking cessation, bariatric surgery, pharmaceutical weight-loss therapies, alternative biomarkers (Ch2), glucose monitoring CGM/SMBG (Ch2)
- **Clinical tier**: T3 (Informational — methodology table)
- **Job ID**: df538e50-0170-4ef8-862d-5b0a7c48e4ff
- **Disagreement flag**: NO

## Extraction Summary
| Metric | Value |
|--------|-------|
| Total spans | 20 |
| T1 (Patient Safety) | 6 |
| T2 (Clinical Accuracy) | 14 |
| T3 (Informational) | 0 |
| Channels present | B (Drug Dictionary), D (Table Decomp), F (NuExtract LLM) |
| Genuinely correct T1 | 0 |
| Genuinely correct T2 | 0 |
| Tier accuracy | 0% (0/20) |
| Disagreements | 0 |
| Review Status | FINAL: 15 ADDED, 7 CONFIRMED, 26 REJECTED |
| Cross-Check | 2026-02-25 — Count corrected 33→20, T1 7→6, T2 26→14; verified against raw extraction data |
| Raw PDF Cross-Check | 2026-02-28 — 7 agent spans CONFIRMED, 26 rejected (D channel table cells + B drug names), 15 gaps added |
| Audit Date | 2026-02-25 (revised) |

## Channel Breakdown
| Channel | Count | Confidence | Content |
|---------|-------|------------|---------|
| D (Table Decomp) | 28 | 92% | Table 2 continuation cells |
| B (Drug Dictionary) | 4 | 100% | Individual drug names from weight-loss therapies list |
| F (NuExtract LLM) | 1 | 90% | HTML comment artifact |

## T1 Spans (7) — ALL MISTIERED

| # | Text | Channel | Conf | Correct Tier | Issue |
|---|------|---------|------|-------------|-------|
| 1 | "miglitol, pramlintide, exenatide, zonamide, fluoxetine, semaglutide, dulaglutide)" | D | 92% | T3 | Table 2 drug list (Intervention cell) — weight-loss therapies PICOM definition |
| 2 | "Weight-loss therapies (olistat, phentermine, saxeda, liraglutide, lorcaserin, bupropion-naltrexone, topiramate, acarbose..." | D | 92% | T3 | Table 2 Intervention cell — full drug list |
| 3 | "Alternative biomarkers (glycated albumin, fructoseamine, carbamylated albumin)" | D | 92% | T3 | Table 2 Intervention cell — Ch2 biomarkers |
| 4 | "liraglutide" | B | 100% | T3 | Drug name from weight-loss list in methods context |
| 5 | "exenatide" | B | 100% | T3 | Drug name from weight-loss list in methods context |
| 6 | "semaglutide" | B | 100% | T3 | Drug name from weight-loss list in methods context |
| 7 | "dulaglutide" | B | 100% | T3 | Drug name from weight-loss list in methods context |

**Analysis**: T1 classification triggered by drug names appearing in PICOM Intervention cells. These define the *scope of systematic review*, not prescribing directives. The B channel extracted 4 individual GLP-1 RA drug names from the weight-loss therapies list — the same drugs it correctly identifies in clinical chapters, but here they're in methodology context.

## T2 Spans (26) — ALL MISTIERED

### Key Duplication
| Extracted Text | Count | Source |
|---------------|-------|--------|
| "None relevant" | 5× | Cochrane systematic reviews column (no existing Cochrane reviews for these topics) |
| "Guideline chapter 2" | 2× | Chapter reference column |
| Supplementary table refs | 6× | Various SoF table references |
| Clinical question texts | 5× | PICOM question for each topic |
| Outcome descriptions | 2× | "All-cause mortality, kidney failure, CKD progression..." |

### Notable D Channel Content
- **Clinical questions** for 6 topics (smoking cessation, bariatric surgery, weight-loss therapies, alternative biomarkers, glucose monitoring)
- **"None relevant"** — no existing Cochrane reviews for smoking, bariatric, weight-loss, biomarkers, or glucose monitoring in CKD+diabetes populations
- **"≥40% decline in eGFR"** — CKD progression threshold in outcome definition
- **"CGM, SMBG"** — monitoring technology abbreviations
- **"(Continued on following page)"** — pagination marker

### F Channel HTML Artifact — 7th Occurrence
`<!-- PAGE 100 -->` at 90% confidence. Running tally: pages 91, 92, 94, 95, 98, 99, 100.

## PDF Source Content Analysis

### Content Present on Page
**Table 2 continuation** — 6 more PICOM questions:

1. **Antiplatelet therapy** (Ch1, continued): Outcomes + study design + "None relevant" Cochrane reviews
2. **Smoking cessation** (Ch3): Smoking-cessation interventions vs usual care — "None relevant"
3. **Bariatric surgery** (Ch3): Bariatric surgery vs usual care — "None relevant"
4. **Pharmaceutical weight-loss** (Ch3): Long drug list (orlistat, phentermine, saxenda, liraglutide, lorcaserin, bupropion-naltrexone, topiramate, acarbose, miglitol, pramlintide, exenatide, zonisamide, fluoxetine, semaglutide, dulaglutide) — "None relevant"
5. **Alternative biomarkers** (Ch2): Glycated albumin, fructosamine, carbamylated albumin vs HbA1c — "None relevant"
6. **Glucose monitoring CGM/SMBG** (Ch2): CGM and SMBG vs HbA1c — "None relevant"

**Key observation**: 5 of 6 clinical questions on this page have "None relevant" Cochrane systematic reviews, indicating these are newer/less-studied topics.

### What Should Have Been Extracted
| Content | Correct Tier | Extracted? |
|---------|-------------|------------|
| Weight-loss drug list (15 drugs) | T3 | YES (D 92%, mistiered as T1) |
| "None relevant" for Cochrane reviews | T3 | YES (D 92%, ×5 — mistiered as T2) |
| Alternative biomarker names | T3 | YES (D 92%, mistiered as T1) |
| CGM/SMBG monitoring terms | T3 | YES (D 92%, mistiered as T2) |
| "≥40% decline in eGFR" outcome criterion | T3 | YES (embedded in outcome text) |

## Quality Assessment

| Dimension | Rating | Notes |
|-----------|--------|-------|
| Extraction completeness | MODERATE | Most Table 2 content captured at cell level |
| Tier accuracy | 0% | All 33 spans should be T3 or NOISE |
| Clinical safety risk | NONE | Methods table — PICOM scope definitions |
| Channel diversity | LOW | 85% D channel |
| Noise level | HIGH | Repetitive table cells, "None relevant" ×5 |
| Pipeline bugs | 1 | HTML comment artifact (7th occurrence) |

## Decision Recommendation
**ACCEPT** — Zero clinical safety risk. Methods table continuation defining systematic review scope.

---

## Raw PDF Cross-Check (2026-02-28)

### Pre-Review State
- **Total spans**: 35
- **ADDED**: 2 (from bulk audit: ">=40% decline in eGFR", "Bariatric surgery")
- **PENDING**: 7 (weight-loss drug lists ×2, outcomes, additional outcomes, alternative biomarkers, smoking-cessation, CGM/SMBG)
- **CONFIRMED**: 0
- **REJECTED**: 26 (D channel table cells + B drug names + F HTML artifact)

### Agent Spans CONFIRMED (7 — from PENDING)
| # | ID | Text | Note |
|---|-----|------|------|
| 1 | `fd8f731d` | Weight-loss therapies (olistat, phentermine, saxeda, liraglutide, lorcaserin, bupropion-naltrexone, topiramate, acarbose... | Weight-loss drug list part 1 — KB-1 |
| 2 | `4a899590` | miglitol, pramlintide, exenatide, zonamide, fluoxetine, semaglutide, dulaglutide) | Weight-loss drug list part 2 — KB-1 |
| 3 | `c6cf78a6` | All-cause mortality, kidney failure, CKD progression-doubling of SCr, >=40% decline in eGFR, mean blood glucose (HbA1c) | Ch2 outcomes — KB-16 |
| 4 | `74bf2c70` | Additional outcomes: blood pressure, body mass index, body weight, fatigue, quality of life | Additional outcomes — KB-16 |
| 5 | `903ee48f` | Alternative biomarkers (glycated albumin, fructoseamine, carbamylated albumin) | Ch2 biomarkers — KB-16 |
| 6 | `15bf7f5d` | Smoking-cessation interventions | Ch1 intervention — KB-4 |
| 7 | `ebc655bf` | Glucose monitoring (CGM, SMBG) | Ch2 monitoring — KB-16 |

### Gaps Added (13) — Exact PDF Text

| # | Gap Text (truncated) | Note |
|---|----------|------|
| G100-A | Do antiplatelet therapies improve clinically relevant outcomes... Comparator: Usual care. Outcomes: Critical and important outcomes listed in Table 1. Additional outcomes: blood pressure, fatigue, quality of life. | PICOM Q6 complete — Antiplatelet (continued from p99) |
| G100-B | Does smoking cessation versus usual care improve clinically relevant outcomes... Additional outcomes: blood pressure, body mass index, body weight, fatigue, quality of life. | PICOM Q7 — Smoking cessation |
| G100-C | Does bariatric surgery versus usual care improve clinically relevant outcomes... | PICOM Q8 — Bariatric surgery |
| G100-D | In patients with diabetes and CKD, do pharmaceutical weight-loss therapies... Intervention: Weight-loss therapies (olistat, phentermine, saxenda, liraglutide, lorcaserin, bupropion-naltrexone, topiramate, acarbose, miglitol, pramlintide, exenatide, zonisamide, fluoxetide, semaglutide, dulaglutide). | PICOM Q9 — Weight-loss therapies |
| G100-E | In adults with diabetes and CKD, compared to HbA1c, do alternative biomarkers improve clinically relevant outcomes... Intervention: Alternative biomarkers (glycated albumin, fructosamine, carbamylated albumin). Comparator: HbA1c or blood glucose monitoring. | PICOM Q10 — Alternative biomarkers Ch2 |
| G100-F | In adults with diabetes and CKD, compared to HbA1c, does blood glucose monitoring (CGM, SMBG) improve clinically relevant outcomes... Comparator: HbA1c. | PICOM Q11 — CGM/SMBG Ch2 |
| G100-G | Table 2 \| (Continued) Clinical questions and systematic review topics in the PICOM format. Guideline chapter 2: Glycemic monitoring and targets in patients with diabetes and CKD. | Table 2 continued header — Ch2 scope |
| G100-H | Supplementary Tables S47-S49 | SoF refs — Antiplatelet |
| G100-I | Supplementary Table S9 | SoF refs — Smoking cessation |
| G100-J | Supplementary Table S57 | SoF refs — Bariatric surgery |
| G100-K | Supplementary Tables S23, S83-S87 | SoF refs — Weight-loss therapies |
| G100-L | Supplementary Table S14 | SoF refs — Alternative biomarkers |
| G100-M | Supplementary Tables S15, S50 | SoF refs — CGM/SMBG |

### Post-Review State
- **Total spans**: 48
- **ADDED**: 15 (2 bulk audit + 13 new gaps)
- **CONFIRMED**: 7 (all from PENDING)
- **REJECTED**: 26 (D channel table cells + B drug names + F artifact)
- **P2-ready facts**: 22

### KB Routing
| Gap | Target KB | Rationale |
|-----|-----------|-----------|
| G100-A | KB-4 (Safety) | Antiplatelet therapy clinical question |
| G100-B, G100-C | KB-4 (Safety) | Lifestyle intervention questions — smoking, bariatric |
| G100-D | KB-1 (Dosing) + KB-4 (Safety) | Weight-loss therapies with 15-drug list |
| G100-E, G100-F | KB-16 (Monitoring) | Ch2 biomarker and glucose monitoring questions |
| G100-G–M | KB-7 (Terminology) | Table header, SoF table references |
| All 7 confirmed spans | KB-1 (Dosing) + KB-16 (Monitoring) | Drug lists, outcome definitions, biomarkers, monitoring |

## Audit Metadata
- **Audited**: 2026-02-24
- **Method**: Playwright browser UI (Phase 2B Page Browse)
- **Auditor**: Claude (automated)
- **Raw PDF Cross-Check**: 2026-02-28 (claude-auditor via API)
- **Page in sequence**: 100 of 126
